Pharsight

Cubicin patents expiration

CUBICIN's oppositions filed in EPO
CUBICIN IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE39071 CUBIST PHARMS LLC Anhydro-and isomer-a-21978c cyclic peptides
Jun, 2016

(8 years ago)

US6852689 CUBIST PHARMS LLC Methods for administration of antibiotics
Sep, 2019

(4 years ago)

US6468967 CUBIST PHARMS LLC Methods for administration of antibiotics
Sep, 2019

(4 years ago)

US8129342 CUBIST PHARMS LLC High purity lipopeptides
Nov, 2020

(3 years ago)

US8058238 CUBIST PHARMS LLC High purity lipopeptides
Nov, 2020

(3 years ago)

US8003673 CUBIST PHARMS LLC Daptomycin for the treatment of biofilm and catheter salvage
Sep, 2028

(4 years from now)

US9138456 CUBIST PHARMS LLC Lipopeptide compositions and related methods
Nov, 2030

(6 years from now)

Cubicin is owned by Cubist Pharms Llc.

Cubicin contains Daptomycin.

Cubicin has a total of 7 drug patents out of which 5 drug patents have expired.

Expired drug patents of Cubicin are:

  • USRE39071
  • US6852689
  • US6468967
  • US8129342
  • US8058238

Cubicin was authorised for market use on 12 September, 2003.

Cubicin is available in powder;intravenous dosage forms.

Cubicin can be used as treatment of the following infections: complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis, method for treating bacterial infection, method of treating bacterial infections.

The generics of Cubicin are possible to be released after 23 November, 2030.

Drug Exclusivity Drug Exclusivity Expiration
M(M-211) Sep 01, 2020
New Patient Population(NPP) Mar 29, 2020

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using DAPTOMYCIN ingredient

Market Authorisation Date: 12 September, 2003

Treatment: Method for treating bacterial infection; Method of treating bacterial infections; Treatment of the following infections: complicated skin and skin structure infections and staphylococcus aureus bloods...

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of CUBICIN before it's drug patent expiration?
More Information on Dosage

CUBICIN family patents

Family Patents